<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rubitecan [Orathecin, 9-nitrocamptothecin, 9NC, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> 2000] is a <z:chebi fb="0" ids="50276">topoisomerase I inhibitor</z:chebi> extracted from the bark and leaves of the Camptotheca acuminata tree, which is native to China </plain></SENT>
<SENT sid="1" pm="."><plain>Rubitecan is an oral compound being developed for the treatment of <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> and other <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> by SuperGen </plain></SENT>
<SENT sid="2" pm="."><plain>One of the major benefits of rubitecan is that it can be administered in an outpatient setting, so patients can be treated in their homes </plain></SENT>
<SENT sid="3" pm="."><plain>Rubitecan was isolated by the Stehlin Foundation in the US </plain></SENT>
<SENT sid="4" pm="."><plain>SuperGen is currently awaiting regulatory approval in the US and the EU for rubitecan in the treatment of <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>At the BIO-2004 conference, SuperGen announced it is seeking a partner for rubitecan for territories outside the US </plain></SENT>
<SENT sid="6" pm="."><plain>SuperGen acquired exclusive worldwide rights to rubitecan from the Stehlin Foundation in 1997 except in Mexico, Canada, Spain, Japan, the UK, France, Italy and Germany </plain></SENT>
<SENT sid="7" pm="."><plain>SuperGen has also received approval from the US FDA to use its own manufactured rubitecan in clinical trials </plain></SENT>
<SENT sid="8" pm="."><plain>SuperGen and the Stehlin Foundation have an 8-year research agreement that secures global rights to other <z:chebi fb="0" ids="27656">camptothecins</z:chebi> and additional anticancer compounds for the former </plain></SENT>
<SENT sid="9" pm="."><plain>In December 1999, SuperGen and Abbott signed a worldwide sales and marketing agreement for rubitecan </plain></SENT>
<SENT sid="10" pm="."><plain>Under the terms of the agreement, Abbott had exclusive distribution and promotion rights for rubitecan outside the US, and co-promotion rights with SuperGen within the US </plain></SENT>
<SENT sid="11" pm="."><plain>In return, Abbott made an initial equity investment in SuperGen </plain></SENT>
<SENT sid="12" pm="."><plain>SuperGen and Abbott Laboratories ended their collaboration agreement in February 2002 by mutual consent with SuperGen stating that the dissolution of the agreement was based on commercial motivation rather than anything to do with rubitecan's safety or efficacy </plain></SENT>
<SENT sid="13" pm="."><plain>Abbott no longer has rights or obligations to purchase shares of SuperGen stock or an option to purchase up to 49% of the company </plain></SENT>
<SENT sid="14" pm="."><plain>For its part, SuperGen will no longer receive milestone payments worth up to $US57 million </plain></SENT>
<SENT sid="15" pm="."><plain>SuperGen has formed a clinical and business alliance with US <z:hpo ids='HP_0002664'>Oncology</z:hpo> (created by the merger between American <z:hpo ids='HP_0002664'>Oncology</z:hpo> Resources and Physician Reliance Network in the US), and will collaborate on clinical trials of rubitecan </plain></SENT>
<SENT sid="16" pm="."><plain>SuperGen believes that this relationship will increase the patient population available for trials and enable it to market the drug directly to Oncologists </plain></SENT>
<SENT sid="17" pm="."><plain>SuperGen and Capital Research and Management Company have completed a $US16.6 million private placement transaction that will enable future funding for the rubitecan programme as well as other <z:hpo ids='HP_0002664'>oncology</z:hpo> programmes </plain></SENT>
<SENT sid="18" pm="."><plain>In July 2004, SuperGen's European subsidiary, EuroGen Pharmaceuticals, submitted a Marketing Authorisation Application for rubitecan in the treatment of <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="19" pm="."><plain>The application will be reviewed under the EMEA Centralised Procedure </plain></SENT>
<SENT sid="20" pm="."><plain>In June 2003, the EMEA granted SuperGen orphan drug status for rubitecan for the treatment of <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="21" pm="."><plain>The US FDA has also granted orphan drug status for rubitecan in the treatment of <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> and fast-track status for rubitecan for the treatment of locally advanced or metastatic <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> that is resistant or refractory to chemotherapy </plain></SENT>
<SENT sid="22" pm="."><plain>SuperGen has conducted three phase III pivotal trials in patients with <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="23" pm="."><plain>A phase III randomised trial in chemotherapy-naive patients was conducted at 132 centres throughout the US </plain></SENT>
<SENT sid="24" pm="."><plain>The trial enrolled approximately 994 patients who were randomised to receive rubitecan or <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> </plain></SENT>
<SENT sid="25" pm="."><plain>Enrollment was completed in October 2001 </plain></SENT>
<SENT sid="26" pm="."><plain>Another phase III trial has compared rubitecan with the most appropriate chemotherapy in chemotherapy-resistant patients </plain></SENT>
<SENT sid="27" pm="."><plain>Enrollment of over 400 patients at 200 medical centres across the US was completed in June 2001 </plain></SENT>
<SENT sid="28" pm="."><plain>Results from the trial were presented at the 39th Annual Meeting of the American Society of Clinical <z:hpo ids='HP_0002664'>Oncology</z:hpo> (ASCO-2003) [Chicago, US; 31 May - 3 June 2003], after they had been compiled, analysed and submitted to the FDA </plain></SENT>
<SENT sid="29" pm="."><plain>The results of the study showed that rubitecan could not help <z:hpo ids='HP_0000001'>all</z:hpo> chemotherapy-resistant patients, but could increase survival in those that do respond </plain></SENT>
<SENT sid="30" pm="."><plain>The other phase III pivotal trial was conducted in patients with <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> who had failed treatment with <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> </plain></SENT>
<SENT sid="31" pm="."><plain>This trial completed enrollment in October 2001, and had enrolled approximately 448 patients </plain></SENT>
<SENT sid="32" pm="."><plain>SuperGen is conducting phase II trials of rubitecan in patients with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> in the UK, Italy, France, Germany, the Netherlands and Denmark </plain></SENT>
<SENT sid="33" pm="."><plain>Each trial will enroll 100-150 patients with various <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types, including colorectal, lung, breast, gastric, prostate, cervical and <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancers</z:e> </plain></SENT>
<SENT sid="34" pm="."><plain>Phase I/II trials are underway to investigate rubitecan as a radiosensitiser in patients with <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e>, and phase II trials in patients with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> are also being conducted </plain></SENT>
<SENT sid="35" pm="."><plain>A phase II study in <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> patients is also being conducted </plain></SENT>
<SENT sid="36" pm="."><plain>Results from an ongoing phase II study in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients have shown that rubitecan was effective against <z:hpo ids='HP_0010762'>chordomas</z:hpo>, a rare type of <z:e sem="disease" ids="C0279530" disease_type="Neoplastic Process" abbrv="">bone cancer</z:e> </plain></SENT>
<SENT sid="37" pm="."><plain>Phase II studies are also underway in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> including <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">preleukaemia</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> </plain></SENT>
<SENT sid="38" pm="."><plain>In February 2000, SuperGen announced that its IND submission for rubitecan had been approved by the Therapeutics Products Programme of Canada </plain></SENT>
<SENT sid="39" pm="."><plain>The company stated that it intended to begin clinical trials in Canada in the near future </plain></SENT>
<SENT sid="40" pm="."><plain>In February 2004, SuperGen announced an offering of shares of its common stock to finance the commercialisation of rubitecan capsules </plain></SENT>
<SENT sid="41" pm="."><plain>In July 2003, SuperGen was granted a US patent covering combination therapies with chemotherapeutic <z:chebi fb="0" ids="48120">anthracycline</z:chebi> agents and structural modifications that may one day lead to next-generation rubitecan compounds </plain></SENT>
<SENT sid="42" pm="."><plain>In December 2002, SuperGen was granted US patent No. 6,482,830, covering its polymorphic formulations of rubitecan </plain></SENT>
<SENT sid="43" pm="."><plain>The patent also covers a class of polymorphs that are similar to the one at the centre of rubitecan </plain></SENT>
<SENT sid="44" pm="."><plain>In addition, SuperGen was also issued US patent No. 6,485,514 in December 2002, covering the local delivery of rubitecan via stents and/or catheters to sites of proliferating cells </plain></SENT>
<SENT sid="45" pm="."><plain>Stent- or catheter-delivered rubitecan may be beneficial in certain types of cardiac procedures, such as ablation or angioplasty, as well as for direct injection into a certain number of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> </plain></SENT>
<SENT sid="46" pm="."><plain>SuperGen is also developing an inhaled, liposomal formulation of rubitecan </plain></SENT>
<SENT sid="47" pm="."><plain>It acquired the worldwide rights to this formulation from the Clayton Foundation in December 1999 </plain></SENT>
<SENT sid="48" pm="."><plain>Inhaled rubitecan is in clinical trials in the US for the treatment of <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> and pulmonary <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e> </plain></SENT>
</text></document>